Abivax: Results from Obefazimod Trials in Ulcerative Colitis

Significant Improvement in Patient-Reported Outcomes

Abivax announced that the phase 3 trials, named ABTECT, for the treatment of ulcerative colitis with Obefazimod have shown significant improvement in patient-reported parameters. According to the data collected up to the eighth week, 37% of patients who received a daily dose of 50 mg of Obefazimod reported an absence of bowel urgency, compared to 18.1% in the placebo group. Additionally, 47.6% of patients in the same group reported no nocturnal stools, versus 24.7% among those taking a placebo. Lastly, a remission of fatigue was noted in 17.1% of patients on Obefazimod, while only 7.7% in the placebo group reported such results.

Importance of Patient-Reported Outcomes (PROs)

Abivax emphasizes the importance of patient-reported outcomes (PROs) to assess the impact of treatments. These PROs include bowel urgency, frequency of nocturnal stools, and fatigue, among others. The results suggest that Obefazimod could improve the overall quality of life for patients, a crucial aspect for those suffering from ulcerative colitis, a disease that can deeply impact daily life, according to Marla Dubinsky, professor at the Icahn School of Medicine in New York. These data will be presented at upcoming medical conferences for further discussion.

Future Plans and Ongoing Trials

Abivax plans to publish more detailed results in the coming months and hopes to present an analysis of the data at medical conferences. Additionally, the company is working on a maintenance trial expected to conclude in the second quarter of 2026. Abivax, specializing in the development of treatments for chronic inflammatory diseases, sees these positive results as an important step towards a potential new therapeutic option for patients suffering from ulcerative colitis. CEO Marc de Garidel highlighted Abivax's commitment to providing more effective and better-tolerated treatments, thus addressing a significant medical need.